查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854176

2型糖尿病药物市场按药物类别、给药途径、治疗线、分销管道、品牌类型、患者年龄层和患者性别划分－全球预测（2025-2032年）

Type 2 Diabetes Drugs Market by Drug Class, Route Of Administration, Treatment Line, Distribution Channel, Brand Type, Patient Age Group, Patient Gender - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，2 型糖尿病药物市场将成长至 1,552 亿美元，复合年增长率为 9.14%。

关键市场统计数据
基准年 2024 770.7亿美元
预计年份：2025年 840.7亿美元
预测年份 2032 1552亿美元
复合年增长率 (%) 9.14%

对现代第2型糖尿病照护格局进行简明策略概述，将临床创新、服务模式和商业性重点连结起来，以引领产业发展。

2型糖尿病是临床上最复杂、商业性最具活力的治疗领域之一，它处于快速治疗创新、不断演变的护理模式以及支付方期望的交汇点。本执行摘要概述了影响产品开发、临床定位和商业性执行的核心趋势，涵盖药理类别、给药途径、治疗线、分销管道和患者群体。其旨在帮助高阶领导者将临床进展和监管趋势转化为切实可行的策略重点。

治疗方法领域的新进展和综合护理服务模式的创新再形成糖尿病护理的临床重点和商业性决策。

2型糖尿病的治疗格局正经历一系列同步转变，这些转变正在影响商业性和临床决策。肠促胰素和钠-葡萄糖共同输送体生物学的突破性进展，使得具有多器官效应的药物数量增加，促使临床医生和支付方从更广泛的心肾代谢角度评估治疗方法。因此，处方决策越来越受到真实世界疗效以及长期发病率和死亡率数据的影响，而不仅仅是血糖值指标。

评估不断变化的进口关税方案将如何影响糖尿病照护价值链的供应韧性、采购经济效益和策略采购决策。

2025年潜在的关税调整和贸易政策转变将为製药企业、经销商和医疗保健系统带来新的营运复杂性。原料药、製剂和给药装置的进口关税提高可能会改变到岸成本，并影响企业在生产区域、库存缓衝和供应商合约方面的决策。如果关税造成永久性的成本差异，企业可能会加快近岸外包和双重筹资策略，以维持供应的连续性和利润率。

将药物类别、给药途径、治疗方案、分销管道、品牌类型和患者人口统计特征与策略问题联繫起来的综合細項分析

详细的細項分析揭示了不同药物类别、给药方式、治疗定位、分销管道、品牌和患者群体的差异化机会和风险。在各类药物中，双胍类药物由于其製剂层面的差异（例如组合药物、缓释性和速释製剂）而发挥着至关重要的作用，这些差异会影响耐受性和依从性。 DPP-4抑制剂则根据特定的分子实体进行区分，例如阿格列汀、Linagliptin、沙格列汀和sitagliptin，每种药物都有不同的安全性和交互作用特征，从而影响处方医生的偏好。 GLP-1受体促效剂表现出显着的异质性，例如Dulaglutide、Exenatide、Liraglutide和Semaglutide等药物，其给药频率、减重效果和心血管讯号会影响治疗选择。胰岛素製剂分为基础製剂、Aspart及预混合料製剂三类，其中包括德谷胰岛素、地特胰岛素及甘精胰岛素等基础製剂；餐前胰岛素製剂如门冬胰岛素、Glulisine及Lispro；以及预混合料製剂如50/50、70/30及75/25混合製剂。 SGLT2抑制剂包括Canagliflozin、Dapagliflozin、Empagliflozin和厄格列净，每种药物的心血管和肾臟结局数据各不相同，这决定了支付方的定价。磺酰尿素类和噻唑烷二酮类药物，包括氯磺丙脲、Glimepiride、Glipizide、格列PIOGLITAZONE脲、吡格列酮和Rosiglitazone酮，在某些临床情况下仍然适用，尤其是在成本和已确定的耐受性是关键考虑因素时。

世界各主要地区在监管严格程度、支付机制和医疗保健基础设施的区域差异，将影响糖尿病药物的推广应用路径。

区域动态以多种方式影响监管时间表、支付方行为和病患就医途径，进而显着影响临床应用和商业性执行。在美洲，监管和支付生态系统的特点是私人和公共支付方之间复杂的互动，以及具有心血管代谢获益的高证据疗法的快速普及，这些因素影响着药品目录的编入和使用管理。该地区还拥有成熟的专科分销管道和先进的数位医疗应用，这可以加速患者对注射疗法和远端剂量调整方案的接受度。

公司策略着重于证据生成、伙伴关係和生产韧性，以在糖尿病治疗中获取临床价值并维持治疗生命週期。

领先的製药和生物技术公司已针对不断变化的糖尿病市场展现出多种战略应对措施，包括重点投资GLP-1和SGLT2生物学、扩大胰岛素生产能力以及整合药物-器械-数位化伙伴关係。许多公司正优先考虑血糖终点以外的证据生成，投资于心血管和肾臟结局研究、真实世界证据项目以及卫生经济学模型，以支持与支付方进行基于价值的合约谈判。在公司层面，生命週期管理策略强调新製剂、给药装置创新和适应症拓展，以维持临床相关性并延长产品寿命。

为加速以病人为中心的治疗方法的推广，同时协调实证医学的产生、医疗资源的保障和支付方的参与，领导阶层需要采取切实可行的策略要务。

产业领导者应采取多管齐下的策略，协调临床差异化、供应可靠性和支付方参与，以维持药物可及性和商业性绩效。首先，优先创建可靠的真实世界证据和结果数据，将治疗药物与降低心血管和肾臟事件发生率联繫起来。其次，多元化筹资策略，加速区域生产，以降低关税和供应链风险，同时保持利润弹性和病患可及性。第三，投资于给药平台创新，例如长效製剂和易于使用的注射器，并结合能够证明其持久性和改善健康结果的数位依从性解决方案。

调查方法框架结合了主要相关人员访谈、严格的二手证据综合和可靠的三角测量，以确保可操作的资讯和分析的严谨性。

本执行摘要依据的分析整合了多项定性和定量研究，以确保得出可靠且可操作的结论。主要研究包括对临床医生、支付方代表、药房负责人和行业高管进行深度访谈，以了解处方行为、报销驱动因素和供应链限制等方面的实际观点。次要研究包括对同行评审的临床试验、监管申报文件、经裁定的结果研究和指南更新进行系统性回顾，以检验治疗定位和安全性讯号。

将临床创新、支付方动态和营运韧性进行综合分析，以指南糖尿病照护生命週期中的策略决策。

整体而言，第2型糖尿病领域呈现出临床创新加速、支付方预期不断变化以及营运压力日益增大的特点，这些都需要采取全面性的策略应对措施。治疗药物，尤其是那些具有良好心血管和肾臟安全性的药物，正在重塑临床模式，而给药方式的创新和数位化支持正在重新定义治疗依从性和连续性。同时，贸易政策的动态和供应链的脆弱性要求采取积极的采购和生产策略，以维持药物的可及性和竞争力。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • GIP/GLP-1促效剂的双重激动剂已显示出优异的血糖控制和减重效果，因此越来越受到关注。
  • 除了血糖控制外，SGLT2抑制剂在心血管和肾臟保护方面的应用日益广泛。
  • 随着人工智慧指导的胰岛素剂量调整和持续血糖监测的融合，个人化糖尿病管理模式正在兴起。
  • 口服Semaglutide越来越受到关注，它能提高第 2 型糖尿病患者的便利性和依从性。
  • 监管部门核准每週一次基础胰岛素类似物，以改善空腹血糖值稳定性并提高患者便利性
  • 开发葡萄糖响应型胰岛素技术，以降低低血糖风险并提高生活品质

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 2型糖尿病药物市场（依药物类别划分）

  • 比瓜尼德斯
    • 复方製剂
    • 加长版
    • 即时发布
  • DPP-4抑制剂
    • 阿格列汀
    • Linagliptin
    • 沙格列汀
    • sitagliptin
  • GLP-1受体促效剂
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Semaglutide
  • 胰岛素
    • 基础药物
      • 德谷
      • 德特米尔
      • 甘精
    • 普兰迪亚尔
      • Aspart
      • Glulisine
      • Lispro
    • 预混合料配方
      • 50/50混合物
      • 70/30 混合
      • 75/25 混合
  • SGLT2抑制剂
    • Canagliflozin
    • Dapagliflozin
    • Empagliflozin
    • 艾格列净
  • 磺酰尿素类
    • 氯丙酰胺
    • Glimepiride
    • Glipizide
    • 格列本脲
  • 噻唑烷二酮
    • PIOGLITAZONE
    • Rosiglitazone

9. 依给药途径分類的第2型糖尿病药物市场

  • 注射
    • 笔
    • 预填充式注射器
  • 口服
    • 胶囊
    • 药片

第十章 依治疗类别分類的第二型糖尿病药物市场

  • 第一选择
    • 组合
      • 双重疗法
      • 三联疗法
    • 单药治疗
  • 第二选择
  • 第三选择

第十一章 依分销管道分類的2型糖尿病药物市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：依品牌类型分類的第二型糖尿病药物市场

  • 原厂产品
  • 非专利的

第十三章：依患者年龄层分類的第2型糖尿病药物市场

  • 18至65岁
  • 65岁或以上

第十四章 依患者性别分類的第二型糖尿病药物市场

  • 女士
  • 男性

第十五章 各地区第二型糖尿病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：按组别分類的第2型糖尿病药物市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国第二型糖尿病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Sanofi SA
    • Merck & Co., Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Johnson & Johnson
    • Pfizer Inc.
    • Novartis AG
    • Daiichi Sankyo Company, Limited
Product Code: MRR-7162E4C3E9C3

The Type 2 Diabetes Drugs Market is projected to grow by USD 155.20 billion at a CAGR of 9.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 77.07 billion
Estimated Year [2025] USD 84.07 billion
Forecast Year [2032] USD 155.20 billion
CAGR (%) 9.14%

Concise strategic overview of the contemporary type 2 diabetes therapeutic environment linking clinical innovation, delivery models, and commercial priorities for leadership

Type 2 diabetes remains among the most clinically complex and commercially dynamic therapeutic areas, with rapid therapeutic innovation intersecting with evolving care models and payer expectations. This executive summary synthesizes core trends shaping product development, clinical positioning, and commercial execution across pharmacological classes, routes of administration, treatment lines, distribution channels, and patient demographics. It is structured to help senior leaders translate clinical progress and regulatory developments into pragmatic strategic priorities.

Across treatment modalities, the landscape is being reshaped by agents that extend beyond glycemic control to address cardiovascular, renal, and weight-related outcomes. At the same time, digitization of care pathways, patient-centric adherence solutions, and evolving reimbursement frameworks are redefining how therapies are adopted and utilized. Stakeholders must balance innovation with access considerations to sustain long-term patient benefit while preserving commercial viability. The following sections unpack transformative shifts, regulatory and trade-related headwinds, segmentation-level insights, regional nuances, corporate strategies, and tactical recommendations to guide leadership decision-making. Each section integrates current clinical and commercial intelligence and highlights implications for portfolio management, supply chain strategy, and stakeholder engagement.

Emerging therapeutic advances and integrated care delivery innovations are reshaping clinical priorities and reshuffling commercial decision levers in diabetes care

The therapeutic landscape for type 2 diabetes is experiencing a set of concurrent, reinforcing shifts that collectively reorient commercial and clinical decision-making. Breakthroughs in incretin and sodium-glucose cotransporter biology have elevated agents with multi-system benefits, prompting clinicians and payers to assess therapies through a broader cardiorenal-metabolic lens. As a consequence, formulary decisions are increasingly influenced by real-world outcomes and long-term morbidity and mortality data rather than immediate glycemic metrics alone.

Simultaneously, the rapid acceptance of long-acting injectable and novel oral formulations has expanded patient choice, necessitating nuanced positioning strategies that align administration mode with adherence patterns and patient preference. Digital therapeutics and remote monitoring are moving from pilot projects toward integrated disease-management solutions, enabling longitudinal adherence support and more granular value demonstration to payers. Parallel to these clinical and technological shifts, competitive dynamics are being reshaped by lifecycle management, biosimilar emergence, and cross-sector partnerships that combine pharmaceutical expertise with devices, diagnostics, and software. Together, these forces are accelerating demand for differentiated evidence generation, adaptive pricing strategies, and targeted provider engagement to realize both clinical benefit and commercial success.

Assessing how evolving import tariff scenarios could alter supply resilience, procurement economics, and strategic sourcing decisions across the diabetes therapeutic value chain

Potential tariff changes and trade policy shifts in 2025 introduce an added dimension of operational complexity for pharmaceutical manufacturers, distributors, and health systems. Increased import duties on active pharmaceutical ingredients, finished formulations, or delivery devices can alter landed costs and influence decisions about production geography, inventory buffers, and supplier contracts. Where tariffs create persistent cost differentials, firms are likely to accelerate nearshoring and dual-sourcing strategies to preserve continuity of supply and margin integrity.

Beyond unit cost implications, tariff-driven supply chain adjustments can elongate lead times and raise the operational premium on quality control and regulatory harmonization across jurisdictions. Payers and integrated delivery networks may respond to higher procurement costs by intensifying formulary management, seeking therapeutic substitutions where clinically appropriate, or renegotiating procurement contracts with manufacturers. For manufacturers, this environment increases the importance of transparent cost-of-goods analysis, scenario planning, and proactive engagement with payers to articulate value propositions tied to long-term health outcomes.

Finally, tariff pressures can intensify collaboration between pharmaceutical companies and contract manufacturers to localize critical production steps, while also amplifying investments in manufacturing efficiency and biologics capacity. For product teams, understanding the interplay between trade policy, supply resilience, and pricing dynamics will be essential for preserving patient access and sustaining lifecycle strategies in the coming years.

Comprehensive segmentation analysis linking drug classes, administration routes, treatment lines, distribution channels, brand typologies, and patient demographics to strategic imperatives

Granular segmentation reveals differentiated opportunities and risks across therapeutic classes, modes of delivery, treatment positioning, channels of distribution, brand status, and patient demographics. Within drug classes, biguanides maintain a foundational role with formulation-level differentiation across combination formulations, extended release, and immediate release options that affect tolerability and adherence profiles. DPP-4 inhibitors differentiate by specific molecular entities such as alogliptin, linagliptin, saxagliptin, and sitagliptin, each presenting distinct safety and interaction profiles that inform prescriber preference. GLP-1 receptor agonists show pronounced heterogeneity driven by agents such as dulaglutide, exenatide, liraglutide, and semaglutide, where dosing frequency, weight-loss effects, and cardiovascular signals influence therapeutic selection. Insulin products are stratified into basal, prandial, and premixed categories, with basal options like degludec, detemir, and glargine, prandial options like aspart, glulisine, and lispro, and premixed formulations spanning 50/50, 70/30, and 75/25 mixes; each subgroup has implications for titration complexity and delivery device compatibility. SGLT2 inhibitors comprise agents such as canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, each with distinct cardiovascular and renal outcome data that shape payer positioning. Sulfonylureas and thiazolidinediones, with constituents like chlorpropamide, glimepiride, glipizide, glyburide, pioglitazone, and rosiglitazone, remain relevant in specific clinical contexts, especially where cost and established tolerability profiles are primary considerations.

Route of administration segmentation distinguishes injectable formats, including pen and prefilled syringe devices, from oral capsules and tablets, and this division materially affects adherence, patient education needs, and device-related supply chain considerations. Treatment line segmentation-first line, second line, and third line-requires careful mapping of combination versus monotherapy strategies, where first-line combination approaches further bifurcate into dual and triple therapy regimens, each presenting unique evidence generation and payer negotiation requirements. Distribution channel dynamics across hospital pharmacy, online pharmacy, and retail pharmacy influence stocking practices, cold chain obligations, and point-of-care education, while brand type segmentation between branded and generic products drives differential pricing, promotion, and lifecycle tactics. Patient demographics such as age cohorts (18 to 65 and above 65) and gender differences (female and male) call for tailored adherence programs, comorbidity-aware treatment selection, and communications calibrated to differing risk profiles and healthcare utilization patterns. Integrating these segmentation layers enables more precise targeting of clinical development, commercial deployment, and outcomes measurement across the full product lifecycle.

Regional variations in regulatory rigor, payer mechanisms, and healthcare infrastructure shape differentiated adoption pathways for diabetes therapies across major global regions

Regional dynamics influence regulatory timelines, payer behavior, and patient access in ways that materially affect clinical adoption and commercial execution. In the Americas, regulatory and payer ecosystems are characterized by rapid uptake of high-evidence therapies that demonstrate cardiorenal-metabolic benefits, alongside a complex interplay between private insurers and public payers that shapes formulary positioning and utilization management. This region also features mature specialty distribution channels and advanced digital health adoption, which can accelerate patient onboarding to injectable therapies and remote titration programs.

The Europe, Middle East & Africa region presents pronounced heterogeneity; western European markets often prioritize robust health economic evidence and health-technology assessments when evaluating new therapies, requiring rich real-world data and cost-effectiveness analyses. Middle Eastern markets frequently focus on expedited access and volume-based procurement models, while African markets face infrastructure constraints and affordability barriers that influence therapy selection and distribution strategies. Navigating this regional mosaic requires tailored regulatory engagement plans and adaptable commercial models that respect local procurement mechanisms and reimbursement pathways.

Asia-Pacific exhibits diverse therapeutic trajectories, with some markets adopting novel agents rapidly due to growing cardiometabolic disease burden and strong primary care networks, while others emphasize local manufacturing and generic substitution to manage costs. In several countries, government-driven initiatives to strengthen diabetes screening and chronic disease management are expanding care pathways, creating opportunities for integrated therapeutic and digital solutions. Across all regions, regional supply chain optimization, evidence localization, and culturally sensitive patient support programs are critical to converting clinical innovation into sustainable patient access.

Corporate strategies converge on evidence generation, partnerships, and manufacturing resilience to capture clinical value and sustain therapeutic lifecycles in diabetes care

Leading pharmaceutical and biotech companies demonstrate a spectrum of strategic responses to the evolving diabetes landscape, including focused investments in GLP-1 and SGLT2 biology, expansion of insulin manufacturing capacity, and partnerships that integrate drug, device, and digital engagement. Many organizations are prioritizing evidence generation beyond glycemic endpoints by investing in cardiovascular and renal outcomes studies, real-world evidence programs, and health-economic modeling to support value-based contracting discussions with payers. At the corporate level, lifecycle management strategies emphasize new formulations, delivery device innovation, and indication expansion to sustain clinical relevance and extend product longevity.

Strategic alliances between established manufacturers and emerging biotech firms are accelerating the translation of novel mechanisms and combination approaches into clinical development. Contract manufacturing and specialized API partnerships are being used to mitigate capacity constraints and diversify supply bases. Companies are also investing in omnichannel commercial models that combine provider education, digital patient support, and targeted field force engagement to improve persistence and adherence. Finally, corporate strategies are increasingly incorporating sustainability and manufacturing resilience objectives to address environmental, social, and governance expectations while reducing operational risk.

Actionable strategic imperatives for leadership to align evidence generation, supply resilience, and payer engagement while accelerating patient-centric adoption of therapies

Industry leaders should adopt a multi-pronged approach that aligns clinical differentiation, supply reliability, and payer engagement to sustain access and commercial performance. First, prioritize generation of robust real-world evidence and outcomes data that link therapies to reductions in cardiovascular and renal events, as this will materially strengthen conversations with payers and integrated health systems. Second, diversify sourcing strategies and accelerate regional manufacturing options to mitigate tariff and supply-chain risk while preserving margin flexibility and patient access. Third, invest in delivery-platform innovation, including long-acting formulations and user-friendly injection devices, paired with digital adherence solutions that demonstrate improvements in persistence and health outcomes.

Additionally, pursue value-based contracting pilots with performance-based reimbursement linked to meaningful clinical endpoints, and tailor these agreements to regional payer expectations and regulatory realities. Optimize channel strategies by strengthening partnerships with hospital pharmacies for acute care settings, online pharmacies for chronic care continuity, and retail partners for community-level access and education. Develop differentiated lifecycle plans that include strategic sequencing of branded innovations and planned generic transitions, accompanied by targeted communication strategies for vulnerable age cohorts and gender-specific adherence interventions. Finally, embed sustainability and quality-by-design principles into operational planning to enhance long-term resilience and stakeholder trust.

Methodological framework combining primary stakeholder interviews, rigorous secondary evidence synthesis, and robust triangulation to ensure actionable intelligence and analytical rigor

The analysis underpinning this executive summary synthesizes multiple qualitative and quantitative research streams to ensure robust and actionable insights. Primary research included in-depth interviews with clinicians, payer representatives, pharmacy leaders, and industry executives to capture frontline perspectives on prescribing behavior, reimbursement drivers, and supply-chain constraints. Secondary research involved a systematic review of peer-reviewed clinical trials, regulatory filings, adjudicated outcomes studies, and guideline updates to verify therapeutic positioning and safety signals.

Data triangulation methods were applied to reconcile insights across sources, with particular emphasis on aligning clinical trial evidence with real-world utilization patterns observed in claims and electronic health record studies. Segmentation mapping incorporated drug class, route of administration, treatment line, distribution channel, brand type, and patient demographics to produce a multidimensional view of adoption dynamics. Quality assurance processes included expert validation sessions and methodological audits to ensure analytical rigor. Limitations are acknowledged where public data are sparse or where evolving regulatory decisions may alter therapeutic trajectories; nevertheless, the methodological framework provides a defensible basis for strategic planning and operational decision-making.

Integrated synthesis of clinical innovation, payer dynamics, and operational resilience to guide strategic decision-making across the diabetes therapy lifecycle

In aggregate, the type 2 diabetes landscape is characterized by accelerating clinical innovation, shifting payer expectations, and operational pressures that together demand integrated strategic responses. Therapies that demonstrate multi-system benefits-particularly those with favorable cardiovascular and renal profiles-are reshaping clinical paradigms, while delivery-mode innovation and digital support are redefining adherence and care continuity. At the same time, trade policy dynamics and supply-chain vulnerabilities require proactive sourcing and manufacturing strategies to maintain access and competitiveness.

Leaders who align evidence generation with pragmatic commercialization tactics, invest in resilient supply chains, and engage payers with outcomes-focused propositions will be best positioned to translate therapeutic advances into sustained patient benefit and organizational value. The insights in this executive summary are designed to inform cross-functional decision-making across clinical development, commercial strategy, supply chain, and policy engagement to navigate near-term disruptions and capture long-term opportunities in diabetes care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising prominence of dual GIP/GLP-1 receptor agonists demonstrating superior glycemic control and weight loss
  • 5.2. Increased adoption of SGLT2 inhibitors for cardiovascular and renal protection beyond glycemic management
  • 5.3. Emergence of personalized diabetes management through continuous glucose monitoring integrated with AI-driven insulin dosing
  • 5.4. Growing focus on oral semaglutide formulations to enhance patient convenience and adherence in type 2 diabetes
  • 5.5. Regulatory approvals for once-weekly basal insulin analogs offering improved fasting glucose stability and patient convenience
  • 5.6. Development of glucose-responsive insulin technologies aimed at reducing hypoglycemia risk and improving quality of life

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Type 2 Diabetes Drugs Market, by Drug Class

  • 8.1. Biguanides
    • 8.1.1. Combination Formulations
    • 8.1.2. Extended Release
    • 8.1.3. Immediate Release
  • 8.2. DPP-4 Inhibitors
    • 8.2.1. Alogliptin
    • 8.2.2. Linagliptin
    • 8.2.3. Saxagliptin
    • 8.2.4. Sitagliptin
  • 8.3. GLP-1 Receptor Agonists
    • 8.3.1. Dulaglutide
    • 8.3.2. Exenatide
    • 8.3.3. Liraglutide
    • 8.3.4. Semaglutide
  • 8.4. Insulin
    • 8.4.1. Basal
      • 8.4.1.1. Degludec
      • 8.4.1.2. Detemir
      • 8.4.1.3. Glargine
    • 8.4.2. Prandial
      • 8.4.2.1. Aspart
      • 8.4.2.2. Glulisine
      • 8.4.2.3. Lispro
    • 8.4.3. Premixed
      • 8.4.3.1. 50/50 Mix
      • 8.4.3.2. 70/30 Mix
      • 8.4.3.3. 75/25 Mix
  • 8.5. SGLT2 Inhibitors
    • 8.5.1. Canagliflozin
    • 8.5.2. Dapagliflozin
    • 8.5.3. Empagliflozin
    • 8.5.4. Ertugliflozin
  • 8.6. Sulfonylureas
    • 8.6.1. Chlorpropamide
    • 8.6.2. Glimepiride
    • 8.6.3. Glipizide
    • 8.6.4. Glyburide
  • 8.7. Thiazolidinediones
    • 8.7.1. Pioglitazone
    • 8.7.2. Rosiglitazone

9. Type 2 Diabetes Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Pen
    • 9.1.2. PreFilled Syringe
  • 9.2. Oral
    • 9.2.1. Capsule
    • 9.2.2. Tablet

10. Type 2 Diabetes Drugs Market, by Treatment Line

  • 10.1. First Line
    • 10.1.1. Combination
      • 10.1.1.1. Dual Therapy
      • 10.1.1.2. Triple Therapy
    • 10.1.2. Monotherapy
  • 10.2. Second Line
  • 10.3. Third Line

11. Type 2 Diabetes Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Type 2 Diabetes Drugs Market, by Brand Type

  • 12.1. Branded
  • 12.2. Generic

13. Type 2 Diabetes Drugs Market, by Patient Age Group

  • 13.1. 18 To 65
  • 13.2. Above 65

14. Type 2 Diabetes Drugs Market, by Patient Gender

  • 14.1. Female
  • 14.2. Male

15. Type 2 Diabetes Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Type 2 Diabetes Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Type 2 Diabetes Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Novo Nordisk A/S
    • 18.3.2. Eli Lilly and Company
    • 18.3.3. Sanofi S.A.
    • 18.3.4. Merck & Co., Inc.
    • 18.3.5. AstraZeneca PLC
    • 18.3.6. Boehringer Ingelheim International GmbH
    • 18.3.7. Johnson & Johnson
    • 18.3.8. Pfizer Inc.
    • 18.3.9. Novartis AG
    • 18.3.10. Daiichi Sankyo Company, Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BRAND TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PATIENT GENDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. TYPE 2 DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. TYPE 2 DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TYPE 2 DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ALOGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LINAGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SAXAGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SITAGLIPTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DULAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EXENATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY BASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DEGLUDEC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DETEMIR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLARGINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PRANDIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ASPART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLULISINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY LISPRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREMIXED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 50/50 MIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 70/30 MIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY 75/25 MIX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CHLORPROPAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIMEPIRIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLIPIZIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY GLYBURIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY THIAZOLIDINEDIONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PIOGLITAZONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROSIGLITAZONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY TREATMENT LINE, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, 2025-2032 (USD MILLION)
  • TABLE 321. GLOBAL TYPE 2 DIABETES DRUGS MARKET SIZE, BY COMBINATION, BY REGION, 2018-202